Pan Z - Search Results

1

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. Honigberg LA, et al. Among authors: pan z. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6. Proc Natl Acad Sci U S A. 2010. PMID: 20615965 Free PMC article.

2

Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.

Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Pan Z, et al. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.

3

Bruton's tyrosine kinase as a drug discovery target.

Pan Z. Pan Z. Drug News Perspect. 2008 Sep;21(7):357-62. doi: 10.1358/dnp.2008.21.7.1255308. Drug News Perspect. 2008. PMID: 19259548 Free article. Review.

4

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.

Ping L, Ding N, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J. Ping L, et al. Among authors: pan z. Oncotarget. 2017 Jun 13;8(24):39218-39229. doi: 10.18632/oncotarget.16836. Oncotarget. 2017. PMID: 28424405 Free PMC article.

5

A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.

Zuo Y, Shi Y, Li X, Teng Y, Pan Z. Zuo Y, et al. Among authors: pan z. Sci Rep. 2015 Nov 4;5:16136. doi: 10.1038/srep16136. Sci Rep. 2015. PMID: 26531233 Free PMC article.

6

The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.

Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J. Li J, et al. Among authors: pan z. Int J Cancer. 2018 Jan 1;142(1):202-213. doi: 10.1002/ijc.31044. Epub 2017 Oct 16. Int J Cancer. 2018. PMID: 28905990 Free article.

7

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. Li X, et al. Among authors: pan z. J Med Chem. 2014 Jun 26;57(12):5112-28. doi: 10.1021/jm4017762. Epub 2014 Jun 10. J Med Chem. 2014. PMID: 24915291

8

Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.

Chen J, Wang X, He F, Pan Z. Chen J, et al. Among authors: pan z. Bioconjug Chem. 2018 May 16;29(5):1640-1645. doi: 10.1021/acs.bioconjchem.8b00137. Epub 2018 Apr 13. Bioconjug Chem. 2018. PMID: 29652138

9

Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.

Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J. Ding N, et al. Among authors: pan z. Oncotarget. 2015 Jun 20;6(17):15122-36. doi: 10.18632/oncotarget.3824. Oncotarget. 2015. PMID: 25944695 Free PMC article.

10

Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).

Fu T, Zuo Y, Zhong Z, Chen X, Pan Z. Fu T, et al. Among authors: pan z. Eur J Med Chem. 2022 Feb 5;229:114051. doi: 10.1016/j.ejmech.2021.114051. Epub 2021 Dec 16. Eur J Med Chem. 2022. PMID: 34952433

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,231 results

Search Page